Enzymatica AB is a Swedish life science company that develops and sells medical devices for infection-related diseases. The products are based on a barrier technology that includes marine enzymes. The Company’s first product is ColdZyme®, a mouth spray which can prevent and reduce the duration of the common cold, alleviate common cold symptoms and improve quality of life. ColdZyme is also effective for throat problems associated with colds. The product has been launched in about ten markets.
The strategy is to continue to grow by strengthening the Company’s position in existing markets and expanding into new geographic markets through established partners. In 2018 Enzymatica entered into new distributor agreements for the sale of ColdZyme in Japan, Hong Kong & Macau and South Africa.